Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches
Open Access
- 30 May 2013
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (11), 2842-2849
- https://doi.org/10.1158/1078-0432.ccr-12-3458
Abstract
The treatment landscape and biologic understanding of neuroendocrine tumors (NET) has shifted dramatically in recent years. Recent studies have shown that somatostatin analogues have the potential not only to control symptoms of hormone hypersecretion but also have the ability to slow tumor growth in patients with advanced carcinoid. The results of clinical trials have further shown that the VEGF pathway inhibitor sunitinib and the mTOR inhibitor everolimus have efficacy in patients with advanced pancreatic NETs. The efficacy of these targeted therapies in NET suggests that the molecular characterization of NETs may provide an avenue to predict both which patients may benefit most from the treatment and to overcome potential drug resistance. Recent genomic studies of NETs have further suggested that pathways regulating chromatin remodeling and epigenetic modification may play a key role in regulating NET growth. These observations offer the potential for new therapeutic and diagnostic advances for patients with NET. Clin Cancer Res; 19(11); 2842–9. ©2013 AACR.Keywords
This publication has 66 references indexed in Scilit:
- Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumorsLaboratory Investigation, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine TumorsGastroenterology, 2011
- mTOR and cancer: many loops in one pathwayCurrent Opinion in Cell Biology, 2010
- Tumor Self-Seeding by Circulating Cancer CellsCell, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsThe New England Journal of Medicine, 2008
- Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathwayThe EMBO Journal, 2006
- Angiogenesis in life, disease and medicineNature, 2005